SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S.
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for
Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B
Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi® revenues were $8.1 million for the second quarter of 2026 Strong revenue growth and
NEW YORK, Aug. 7, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Fortress Biotech, Inc. (NASDAQ:FBIO) concerning possible breaches of fiduciary duties. If you are a current
SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on
MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress'
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27
SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders
SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on
